Lenacapavir was approved for medical use in European Union in August-2022, Lenacapavir is the first of a new class of drugs called "Capsid inhibitors to be FDA-approved for treating HIV/AIDS. Lenacapavir a new type of antiretroviral medication for adult patients living with Human Immunodeficiency Virus type-1(HIV-1), who’s HIV Infections cannot be successfully treated with other available treatments due to resistance, intolerance considerations. Lenacapavir works by blocking the HIV-1 virus' protein shell (the Capsid) .Lenacapvir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type-1 (HIV-1)-Infection. Lenacapvir first formulation Oral Tablets and Subcutaneous injection-form at trade Name-(Sunlenac), Lenacapavir -is achieved in HIV RNA suppression .Lenacapvir is a long- acting, potent inhibitor of the HIV Capsid protein. Lenacapavir binds directly to HIV-capsid in a pocket between capsid protein subunits in hexamers.Treatement of emergent resistance to lenacapvir has been reported in the phase 2/3 CAPELLA trail evaluating Lenacapvir for HIV treatment. Combination antiretroviral therapy-suppression HIV-1 replication and increase CD 4+ cell counts.
Article Details
Unique Paper ID: 158616
Publication Volume & Issue: Volume 9, Issue 10
Page(s): 251 - 265
Article Preview & Download
Share This Article
Conference Alert
NCSST-2021
AICTE Sponsored National Conference on Smart Systems and Technologies
Last Date: 25th November 2021
SWEC- Management
LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT